Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy

Carla De Giovanni, Giordano Nicoletti, Lorena Landuzzi, Stefania Croci, Arianna Palladini, Agnese Antognoli, Annalisa Murgo, Marianna L. Ianzano, Valentina Grosso, Valeria Stivani, Manuela Iezzi, Piero Musiani, Patrizia Nanni, Pier Luigi Lollini

Research output: Contribution to journalArticlepeer-review

Abstract

The possible interference of tamoxifen with anti-tumor vaccines was studied in a translational view of combined preventive approaches. Tamoxifen treatment of HER-2/neu transgenic mice combined to anti-HER-2/neu cell vaccine did not hamper the efficacy of cancer immunoprevention, and caused a significantly increased production of interferon-γ. These data suggest that tamoxifen could even have a positive impact on the efficacy of cancer immunoprevention.

Original languageEnglish
Pages (from-to)2065-2069
Number of pages5
JournalVaccine
Volume27
Issue number14
DOIs
Publication statusPublished - Mar 23 2009

Keywords

  • Breast cancer
  • Tamoxifen
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy'. Together they form a unique fingerprint.

Cite this